IND Application for Study of ATG-022 in Combination with KEYTRUDA® Granted Approval
December 3, 2025
Source: drugdu
53
On December 2nd, Antengene (06996) announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a Phase IB/II study of ATG-022 in combination with KEYTRUDA® (pembrolizumab) and chemotherapy.
This approval will help advance the company’s R&D efforts in treating diseases with unmet medical needs. In the announcement, the company mentioned that ATG-022 is a CLDN18.2 antibody-drug conjugate (ADC), and the study combining it with MSD's anti-PD1 therapy KEYTRUDA® will provide new treatment options for patients. The approval of this study marks further progress for the company in the biotechnology field and enhances its competitiveness in the market.
https://finance.eastmoney.com/a/202512023580471418.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
